| abstract |
The compounds of formula (I) :( see formula I) or pharmaceutically acceptable salts or solvates thereof, wherein R1 represents C1-4; R 2 represents halo, C 1-4 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -SO 2 (C 1-4 alkyl) optionally substituted C 1-4 alkyloxy, Het or -Ohet; R3 represents a bicyclic group of formula (see formula) in which X and Y are selected from C and N, with the proviso that at least one is C; Ring A together with X and Y represents a 5 or 6-membered aromatic ring containing 0, 1, 2 or 3 nitrogen atoms in the ring; n is 0, 1 or 2; L independently represents a direct bond, C1-4 alkylene or C1-4 alkoxyalkylene; R4 independently represents H, -NR5R6, C3-6 cycloalkyl, -OR7, Het1 or Het4; R 5 and R 6 are independently selected from H, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene (C 1-4 alkyl) and optionally substituted C 1-4 alkyl; R7 is selected from H, C1-4 alkyl, C1-4 alkoxyalkyl, C3-6 cycloalkyl Het2 and C1-4 alkyl-Het3; R8 is H or C1-4 alkyl; Het, Het1, Het2 and Het3 independently represent an optionally substituted 4- to 7-membered saturated heterocyclic group that may be mono- or bicyclic and that contains one or more heteroatoms selected from N, O or S; Het4 represents an optionally substituted 5 or 6-membered unsaturated heterocyclic group containing one or more heteroatoms selected from N, O or S; R9 is H or C1-4 alkyl; R10 and R11 are independently selected from H and C1-4 alkyl; they are useful in the treatment of hypertension, myocardial infarction, male erectile dysfunction (MED), hyperlipidemia, cardiac arrhythmia, glaucoma and benign prostatic hyperplasia (BPH); They also find utility in the treatment of female sexual arousal dysfunction (FSAD). |